Physician profile
Mohamed Kamel Mohamed
NPI 1346293784
$841,352.89
in general payments reported to CMS, 2019-2025
32 companies · $66K in 2025
The $66K reported for 2025 was more than what 96% of Hematology (Internal Medicine) providers received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $148K · 2020: $68K · 2021: $139K · 2022: $176K · 2023: $152K · 2024: $92K · 2025: $66K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $204K · Travel and Lodging: $33K · Consulting Fee: $30K · Honoraria: $29K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $8,775 · Food and Beverage: $6,565 · Education: $15.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $203,583.52 |
| Travel and Lodging | $32,584.23 |
| Consulting Fee | $29,564.50 |
| Honoraria | $29,175.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $8,775.00 |
| Food and Beverage | $6,565.09 |
| Education | $15.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $198,398.25 | 2019-2025 | Tagrisso, Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $127,049.89 | 2019-2025 | Opdivo |
| Regeneron Healthcare Solutions, INC. | $102,599.10 | 2021-2025 | Libtayo |
| Lilly USA, LLC | $96,545.91 | 2019-2023 | Retevmo |
| G1 Therapeutics, INC. | $85,094.76 | 2022-2023 | Cosela |
| Genzyme Corporation | $49,944.58 | 2021-2023 | |
| Mirati Therapeutics, INC. | $38,838.17 | 2023-2024 | Krazati |
| Janssen Biotech, INC. | $26,491.79 | 2021-2025 | Rybrevant, Carvykti |
| Merck Sharp & Dohme LLC | $22,688.79 | 2019-2021 | |
| Amgen INC. | $19,156.98 | 2021-2023 | Lumakras |
| Abbvie INC. | $14,220.88 | 2024-2025 | |
| Pharmacosmos Therapeutics INC. | $13,116.70 | 2025 | Cosela |
| Novocure INC. | $11,230.80 | 2024 | Optune Lua (Novottf-200t) |
| Boehringer Ingelheim Pharmaceuticals, INC. | $9,022.01 | 2019 | |
| Pfizer INC. | $7,083.98 | 2019-2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $5,164.89 | 2023-2024 | Enhertu, Enhertu |
| Eli Lilly and Company | $4,907.33 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $2,654.31 | 2020 | |
| Genentech USA, INC. | $2,353.40 | 2019-2021 | |
| Celgene Corporation | $1,908.26 | 2021-2022 | |
| Emd Serono, INC. | $1,725.00 | 2025 | |
| Alexion Pharmaceuticals, INC. | $265.00 | 2019-2020 | |
| Galvanize Therapeutics, INC | $241.98 | 2024-2025 | Aliya System |
| Intuitive Surgical, INC. | $173.20 | 2022 | |
| Auris Health, INC. | $119.92 | 2019 | |
| Caris Mpi, INC. | $107.22 | 2025 | Mi Cancer Seek |
| Astellas Pharma Global Development | $98.27 | 2023 | Padcev |
| Abbott Laboratories | $95.00 | 2025 | Assurity |
| Incyte Corporation | $20.52 | 2019 | |
| Supernus Pharmaceuticals, INC. | $20.01 | 2024 | Qelbree |
| Legend Biotech USA INC. | $15.99 | 2025 | Carvykti |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohamed Mohamed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.